MEX-NM-301 clinical study opens at I-Motion. This open-label, non-comparative phase III study aims to evaluate the steady-state pharmacokinetics, safety, and efficacy of Mexiletine in adolescents and children with Myotonic disorders.
Mexiletine is a sodium channel blocker indicated, in adult, in France, for the symptomatic treatment of myotonic syndromes (myotonic dystrophies and non-dystrophic myotonias or channelopathies).
> Further details on MEX-NM-301